Last reviewed · How we verify
Sanofi Pasteur Menactra® vaccine
Menactra is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by presenting polysaccharide antigens linked to a carrier protein.
Menactra is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by presenting polysaccharide antigens linked to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in individuals 9 months of age and older.
At a glance
| Generic name | Sanofi Pasteur Menactra® vaccine |
|---|---|
| Sponsor | Walvax Biotechnology Co., Ltd. |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis capsular polysaccharides (serogroups A, C, W, Y) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y conjugated to diphtheria toxoid as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in production of protective antibodies against these meningococcal strains and providing long-term immunity against invasive meningococcal disease.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y in individuals 9 months of age and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site induration
- Headache
- Fatigue
- Myalgia
- Fever
Key clinical trials
- A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years (PHASE4)
- Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanofi Pasteur Menactra® vaccine CI brief — competitive landscape report
- Sanofi Pasteur Menactra® vaccine updates RSS · CI watch RSS
- Walvax Biotechnology Co., Ltd. portfolio CI